SCHEMBL791249

SCHEMBL791249

C[C@H](C(=O)O)[C@@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55047 1.00
SCHEMBL1041254 1.00
SCHEMBL2107037 1.00
SCHEMBL55048 1.00
SCHEMBL2932270 1.00
SCHEMBL5549445 1.00
SCHEMBL3518225 1.00
SCHEMBL2687210 1.00
Ammonia Solution, Strong SCHEMBL2340361 0.97
SCHEMBL28118146 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235691-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USE THEROF EICOSIS, LLC (US) 2025-11-13 WO disclosed
US-20240207355-A1 PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTICANCER EFFECT OF ANTICANCER DRUG L-Base Co., Ltd. (KR) 2024-06-27 US disclosed
US-20230159587-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER L-Base Co., Ltd. (KR) 2023-05-25 US disclosed
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 US disclosed
US-11268966-B2 Biomarkers of autism spectrum disorder STEMINA BIOMARKER DISCOVERY, INC. (US) 2022-03-08 US disclosed
EP-3019624-B1 BIOMARKERS OF AUTISM SPECTRUM DISORDER STEMINA BIOMARKER DISCOVERY INC (US) 2020-09-16 EP disclosed
US-20190072569-A1 BIOMARKERS OF AUTISM SPECTRUM DISORDER STEMINA BIOMARKER DISCOVERY, INC. 2019-03-07 US disclosed
US-10060932-B2 Biomarkers of autism spectrum disorder STEMINA BIOMARKER DISCOVERY, INC. (US) 2018-08-28 US disclosed
US-20180179217-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2018-06-28 US disclosed
US-9994614-B2 N-methyl-D-aspartate receptor modulators and methods of making and using same NAUREX, INC. (US) 2018-06-12 US disclosed
US-20070060510-A1 Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2007-03-15 US disclosed
US-7176208-B2 Prevent reproduction of hepatitis virus ENANTA PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-7173004-B2 Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 US disclosed
EP-0774452-B1 Optically active compounds having plural chiral centers and the production thereof CHISSO CORP (JP) 2000-01-26 EP disclosed
EP-0428392-B1 Processes for the preparation of optically active compounds having plural chiral centers CHISSO CORP (JP) 1998-05-27 EP disclosed
EP-0774452-A1 Optically active compounds having plural chiral centers and the production thereof Chisso Corporation (JP) 1997-05-21 EP disclosed
US-5574182-A HYDROLYSING 3-HYDROXYCARBOXYLIC ACID, CYCLIZING ESTER TO FORM 1,3-DIOXAN-4-ONE, DECYCLIZATION AND ESTERIFICATION CHISSO CORPORATION (JP) 1996-11-12 US disclosed
US-5411877-A Esterification CHISSO CORPORATION (JP) 1995-05-02 US disclosed
US-5348870-A Using hydrolase to effect ester interchange and resolution, then alcoholysis or hydrolysis and dehydration with cyclization and crystallization CHISSO CORPORATION (JP) 1994-09-20 US disclosed
EP-0428392-A2 Optically active compounds having plural chiral centers and the production thereof Chisso Corporation (JP) 1991-05-22 EP disclosed